Background: GH deficiency (GHD) is common among childhood cancer survivors (CCSs) with history of tumors, surgery, and/or radiotherapy involving the hypothalamus-pituitary region. We aimed to evaluate the effects of GH therapy (GHT) in CCSs on adult height, risk of diabetes mellitus, abnormal lipids, metabolic syndrome, quality of life, secondary tumors, and disease recurrence.
Results: We included 29 observational studies at moderate to high risk of bias. Sixteen studies compared CCSs on GHT with those not on GHT (512 patients, GH dose: 0.3 to 0.9 IU/kg/week). GHT was significantly associated with height gain [standard deviation score, 0.61; 95% CI, 0.08 to 1.13] and was not significantly associated with the occurrence of secondary tumors [odds ratio (OR), 1.10; 95% CI, 0.72 to 1.67] or tumor recurrence (OR, 0.57; 95% CI, 0.31 to 1.02). Thirteen studies compared CCSs on GHT with normal age-or sex-matched controls or controls with idiopathic GHD or short stature. GHT was associated with either improved or unchanged risk of diabetes, lipid profiles, and metabolic syndrome. GHT was associated with improvements in quality of life.
Conclusion: CCSs treated with GHT gain height compared with the untreated controls. GHT may improve lipid profiles and quality of life and does not appear to increase the risk of diabetes or the development of secondary tumors, although close monitoring for such complications remains warranted due to uncertainty in the current evidence. (J Clin Endocrinol Metab 103: [2794] [2795] [2796] [2797] [2798] [2799] [2800] [2801] 2018) T he survival rates of children treated for cancer have improved significantly over the years. GH deficiency (GHD) is common among these children, especially among childhood cancer survivors (CCSs) with tumors/ surgery in the hypothalamic-pituitary (HP) region, CCSs exposed to HP radiation or CCSs exposed to cranial (CIR), craniospinal (CSI), or total body irradiation.
GHD is one of the most common endocrinopathies observed in CCSs with a history of central nervous system tumors. Studies have shown that cancer and its treatments negatively affect adult height and that CCSs may not fully recover their growth potential even after growth hormone therapy (GHT) (1) . In addition to its impact on linear growth, GHD has been shown to increase cardiovascular risk and impair quality of life (QOL); however, no studies assessing such outcomes have been conducted specifically in CCSs (2, 3) . Given the toxicity of cancer treatments, the contribution of GHD to poor health outcomes in CCSs is debatable, and whether GHT reverses these findings is unknown. Pituitary-derived human GH was used between 1958 and 1984 to treat GHD. Recombinant hGH (r-hGH) was approved for clinical use in the United States in 1985 (4) and has been used to treat GHD in CCSs. There have been continued concerns that GHT may increase the risk of tumor recurrence, secondary tumors, and other adverse effects.
To support the Endocrine Society guidelines on the management of CCSs, we conducted this systematic review and meta-analysis to evaluate the effects of GHT in CCSs with tumors/surgery in the HP region and on CCSs subjected to CIR, CSI, or total body irradiation at a young age on adult height, risk of diabetes mellitus, lipid abnormalities, metabolic syndrome, QOL, secondary tumors, and disease recurrence.
Methods
The protocol for this systematic review was developed in collaboration with members of a taskforce from the Endocrine society. This report follows the standards set in the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement (5).
Eligibility criteria
We searched for cohort studies, case series, randomized clinical trials, and meta-analysis evaluating outcomes related to adult height, risk of diabetes mellitus, abnormal lipids, metabolic syndrome, QOL, secondary tumors, and disease recurrence in CCSs receiving GHT compared with those not receiving GHT. There was no language restriction, and we excluded studies with missing data despite author contact. Because we anticipated the number of eligible studies to be small, we also sought additional studies that reported the outcomes of interest in CCSs receiving GHT if they had other control groups. We summarized such studies narratively and considered them as indirect supporting evidence.
Study identification
A comprehensive search that included the Ovid Medline InProcess & Other Non-Indexed Citations, Ovid EMBASE, Web of Science, and Scopus databases was conducted beginning from each database's inception to January 2016. The search strategy was designed by a medical reference librarian with input from the study investigators. Controlled vocabulary supplemented with keywords was used to search for studies evaluating the selected outcomes in CCSs. We consulted experts in the field, references from primary studies, and Google Scholar to identify studies missed by our search strategy. Studies that were referred by the expert panel through May 2017 were also assessed.
Selection of studies
Reviewers working independently and in duplicate reviewed all abstracts and selected full-text manuscripts for eligibility.
Disagreements during the full-text screening were resolved by consensus.
Data collection and management
Working independently and in duplicate, reviewers used a standardized Web-based form to collect information from each eligible study. For each study, the baseline clinical features of the included population, such as age, type of tumor, radiation details, serum GH levels, GH dose, and duration of GHT, were recorded. The outcomes of interest were focused on adult height, risk of diabetes mellitus, abnormal lipids, metabolic syndrome, QOL, secondary tumors, disease recurrence, and mortality.
Risk of bias and quality of evidence
The risk of bias was assessed by reviewers working independently and in duplicate using a modified Newcastle-Ottawa scale (6) for observational studies. Disagreements were resolved by consensus. The quality of evidence (certainty in the estimate) was graded using the Grading of Recommendation, Assessment, Development, and Evaluation approach (7).
Summary measures and synthesis of results
We performed a meta-analysis of each of the outcomes of interest using a random effects model (8) . The adjusted relative risks were used preferentially if available in the studies. We used the I 2 statistic to assess heterogeneity across individual studies, and I 2 . 50% indicated a large inconsistency across studies not explained by chance. Statistical analysis was performed using STATA, version 13.1 (StataCorp LP, College Station, TX).
Results

Search results
We included 29 observational studies (Fig. 1) . Sixteen studies at moderate-to-high risk of bias (Supplemental Table 3 ) contributed data to the meta-analysis and had a control group of CCSs not treated with GHT. The characteristics of the studies and descriptions of the patients are included in Supplemental Tables 1 and 2 , respectively. Thirteen additional studies on GHT in CCSs (Supplemental Table 3 ) were not included in the meta-analysis because they did not have the control group of interest (CCSs not treated with GHT) but rather had one of the following control groups: (1) idiopathic GHD, (2) non-GH-related short stature, (3) pituitary cause of GHD and GHT, or (4) normal age-or sex-matched general population.
Meta-analysis
The analysis included 512 patients who received an average GH dose of 0.3 to 0.9 IU/kg/week; using the conversion formula of 3.0 IU per 1 mg for r-hGH where applicable, the average dose received was 0.1 to 0.3 mg/kg/ week (9) . CCSs who were treated with GHT had significant height gains compared with those not treated with GHT [weighted mean difference, 0.61; 95% CI, 0.08 to 1.13; n = 6 studies; Fig. 2 ]. There was no statistically significant difference in the occurrence of secondary tumors with GHT (odds ratio, 1.10; 95% CI, 0.72 to 1.67; 5 studies; Fig. 3 ) and no increased risk of disease/tumor recurrence (odds ratio, 0.57; 95% CI, 0.31 to 1.02; 8 studies; Fig. 4) .
Heterogeneity was substantial for height analysis (I 2 .
90%
) and, to a lesser extent, tumor recurrence analysis (I 2 . 60%). The analysis of secondary tumors was homogeneous (I 2 = 0%).
Studies comparing CCSs on GHT with other populations
Summary of the outcomes related to adult height, diabetes mellitus, lipid profile abnormalities, metabolic syndrome, QOL, secondary tumors, disease recurrence, and mortality are provided in Supplemental Tables 2.1 to 2.8.
The studies showed either an improvement or no difference in the risk of diabetes, lipid profile abnormalities, metabolic syndrome, and QOL in CCSs compared with the control groups.
Effect modifiers of height outcome
Adult height was positively correlated with the age at tumor therapy completion (10), height at the start of GHT (10, 11), height standard deviation score gain after the first year of GHT (10), age at diagnosis (1), age at irradiation (1, 12) , target height (1, 13), dose of GHT (13), lower dose of radiation (14) , and cotreatment with a GnRH agonist (12) . Adult height was negatively correlated with CSI (10), spinal radiation (12) and dose (13) , chemotherapy (12) , and the presence of other endocrinopathies (13) .
Methodological quality of studies and overall quality of evidence
The included studies had overall moderate risks of bias that were primarily related to the inability to control the analysis for confounders, making the pooled estimates unadjusted (Supplemental Table 3 ). The quality of evidence (i.e., certainty in these estimates) was low because of the observational nature of the evidence, moderate risk of bias, and imprecision (small number of events).
Discussion
Main findings
GHT in CCSs is associated with a statistically significant gain in height and no apparent increases in the occurrence of secondary tumors or recurrence. There was either an improvement or no difference in the risk of diabetes, lipid fractions, metabolic syndrome, and QOL.
The effect of GHT on height was heterogeneous as demonstrated by statistical measures of heterogeneity. One study (10) showed that GHT failed to restore adult height to the midparental height in nearly one-half of CCSs with radiation-induced GHD, especially in those irradiated at a young age or were short at the start of GHT. None of the patients in another study achieved his or her genetic potential height (15) . The growth increment varied inversely to spontaneous GH secretion in one study (16) . Another study noted that height velocity improved with GHT, with better results obtained in those who received CIR vs craniospinal radiation (17) , likely because of a direct growth plate injury affecting the vertebral growth plates (18) . Compared with patients with idiopathic GHD treated with GHT in the studies evaluated, CCSs treated with GHT (11, 16) showed either lower height gain or comparable growth velocity (19) . In patients with medulloblastoma, adult heights but not sitting heights were improved with GHT (14, 20) . Therefore, CCSs obviously gain variable improvements in height based on other factors, such as spinal injury (radiotherapy, scoliosis).
There is limited literature on the cardiovascular and metabolic effects of GHT in CCSs. Murray (21) showed that CCS patients with GHD had adverse lipid profiles, with significantly higher total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels; however, after 12 months of GHT, there was no significant difference in the HbA1c and serum lipid values in these patients compared with those in the controls. However, small (but important) improvements were observed in body composition in the male subgroup and total cholesterol and triglyceride levels in the female subgroup. In another study on survivors of acute lymphoblastic leukemia (22), 5 years of GHT improved the plasma glucose levels, high-density lipoprotein cholesterol levels, ApoB/ApoA1 ratio, and prevalence of metabolic syndrome (compared with an untreated control group).
The QOL in CCSs on GHT improved dramatically by 3 months; this improvement was maintained at 12 months (21). Similar improvements across QOL domains were observed in CCSs on GHT compared with those in CCSs not treated with GHT at early (6 to 13 months) and long-term (24 to 77 months) follow-ups (23) . The study on survivors of acute lymphoblastic leukemia (22) , however, showed no substantial difference in QOL.
The risk of secondary tumors associated with GHT in CCSs was not statistically increased across all studies; however, considering the imprecision of the estimates, the CI did exclude an important increase in risk. Most of these https://academic.oup.com/jcemtumors were meningiomas (24, 25) . The risk of secondary neoplasms in CCSs treated with GHT was lower after an extended follow-up (26) and became nonsignificant after adjusting for sex, age at primary diagnosis, CIR dose/time, and treatment type in a more recent report from the same cohort (27) . Factors associated with meningioma development included female sex, young age at primary cancer diagnosis, and long periods since CIR (gliomas were associated with short periods since CIR). A report from the Pediatric Endocrine Society Drug and Therapeutic Committee suggested that GHT may increase the risk of subsequent neoplasms (28) . In the aforementioned Pediatric Endocrine Society report, there was also no substantial difference in the risk of recurrence in CCSs treated with GHT vs that in the controls. The outcomes of many individual studies (17, 24, 26, (29) (30) (31) have shown that the risk of recurrence in CCSs treated with GHT is not significantly different than that in CCSs not treated with GHT. Similar outcomes have been seen in medulloblastoma (32) , craniopharyngioma (33) , and acute lymphoblastic leukemia survivors (34) . Two studies (26, 35) showed that the risk of recurrence after GHT was decreased compared with that in untreated patients. In these studies, however, the potential for bias in selecting patients with better prognosis for GHT and use of the last clinical contact as the date of exit from the study must be considered. The dose of GH and treatment modalities did not differ significantly between patients with and without recurrence (31) , and there were no apparent increased risk of recurrence with the cumulative time that GHT was administered or the time elapsed since the treatment started (35) . There have been no definitive studies on how long to wait after the completion of cancer therapy to start GHT; the Pediatric Endocrine Society guidelines suggest waiting for 12 months (9) .
One study suggested a lower mortality for GH-treated patients compared with that for untreated patients, adjusting for potentially confounding prognostic variables (35) . Mortality increased significantly with the time since the first GH treatment, and GH treatment had no effect on 3-year event-free survival rates. Increased mortality from cancer following GHT was reported in a recent report from the Safety and Appropriateness of Growth Hormone Treatments in Europe cohort; this increase was largely attributed to mortality from second cancers in CCSs (36) . The study also reported that cancer mortality rates increased with increasing mean daily r-hGH doses, specifically in CCSs; these data, however, should be interpreted with caution because the cohort did not include CCSs who were not treated with GH and was not designed to specifically assess the risk of secondary neoplasia in CCSs. 
Limitations and strengths
The strengths of this review relate to the comprehensive literature search, an a priori-established protocol and the duplicate process of study selection and appraisal. However, the available studies were observational with inherent limitations. Most studies assessing GHT have a relatively short follow-up duration (17, 30, (37) (38) (39) (40) , which can affect the outcome assessment dealing with the risk of recurrence and the incidence of secondary neoplasms. In the study by Swerdlow (36), however, there was no indication of increased cancer risk with longer follow-up durations. Furthermore, the relationship between the dose and duration response of GHT and cancer risks has been clearly evaluated in only a few studies (36, 41) , which did not note increased cancer risks. The meta-analysis for outcomes related to height and recurrence risks has moderate to high heterogeneity.
Conclusion
GHT is effective in increasing height in CCSs with GHD. From the limited data available, no increased cardiovascular or metabolic risks were obviously associated with GHT, but short follow-up time must be considered a limitation. Although this meta-analysis did not show increased risks of recurrence or secondary neoplasms, additional studies on these risks are necessary.
